Methods of Sentinel Lymph Node Detection and Management in Urinary Bladder Cancer-A Narrative Review.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
23 02 2022
Historique:
received: 05 01 2022
revised: 17 02 2022
accepted: 21 02 2022
entrez: 24 3 2022
pubmed: 25 3 2022
medline: 15 4 2022
Statut: epublish

Résumé

Detection of lymph node status in bladder cancer significantly impacts clinical decisions regarding its management. There is a wide range of detection modalities for this task, including lymphoscintigraphy, computed tomography, magnetic resonance imaging, single-photon emission computed tomography, positron emission tomography, and fluoroscopy. We aimed to study the pre- and intraoperative detection modalities of sentinel lymph nodes in urinary bladder cancer. This narrative review was performed by searching the PubMed and EMBASE libraries using the following search terms: ("Transitional cell carcinoma of the bladder" OR "urothelial cancer" OR "urinary bladder cancer" OR "bladder cancer") AND (("sentinel lymph node") OR ("lymphatic mapping") OR ("lymphoscintigraphy") OR ("lymphangiography") OR ("lymph node metastases")). Studies analysing the effectiveness and outcomes of sentinel lymph node detection in bladder cancer were included, while non-English language, duplicates, and non-article studies were excluded. After analysing the libraries and a further manual search of bibliographies, 31 studies were included in this paper. We followed the RAMESES publication standard for narrative reviews to produce this paper. Of the 31 studies included, 7 studies included multiple detection methods; 5 studies included lymphoscintigraphy; 5 studies included computed tomography and/or single-photon emission computed tomography; 5 studies included fluoroscopy; 4 studies included magnetic resonance imaging; and 5 studies included positron emission tomography. Anatomical, radioactive, and functional detection modalities have been studied independently and in combination. The consensus is that preoperative detection with imaging helps guide surgical management and intraoperative detection methods help capture any lymph nodes that may have been missed. Each of these types of detection represent their own set of benefits and drawbacks, but there is currently limited evidence to support any change in overall practice to replace conventional staging.

Identifiants

pubmed: 35323314
pii: curroncol29030114
doi: 10.3390/curroncol29030114
pmc: PMC8947662
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1335-1348

Références

Rev Esp Med Nucl. 2010 Mar-Apr;29(2):73-7
pubmed: 19931946
Gynecol Oncol. 2014 May;133(2):274-7
pubmed: 24582865
Eur Urol. 2007 Dec;52(6):1700-8
pubmed: 17646044
World J Surg Oncol. 2019 Dec 21;17(1):225
pubmed: 31864368
EBioMedicine. 2018 Aug;34:76-84
pubmed: 30078735
Breast Cancer Res. 2001;3(2):109-12
pubmed: 11250756
J Nucl Med. 2009 Jun;50(6):865-70
pubmed: 19443579
Urol Int. 2019;103(4):373-382
pubmed: 30836375
J Urol. 2006 Jan;175(1):84-8; discussion 88-9
pubmed: 16406877
Eur Urol. 2006 Jul;50(1):83-91
pubmed: 16632191
Nucl Med Commun. 2013 Jun;34(6):590-6
pubmed: 23542912
Ann Surg Oncol. 2012 Nov;19(12):3906-12
pubmed: 22576065
Clin Cancer Res. 2017 Nov 15;23(22):6904-6911
pubmed: 28874414
J Adv Nurs. 2013 May;69(5):987-1004
pubmed: 23356699
J Urol. 1999 May;161(5):1494-7
pubmed: 10210380
Medicina (Kaunas). 2021 Apr 25;57(5):
pubmed: 33922894
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Breast. 2014 Apr;23(2):175-9
pubmed: 24484967
Ann Nucl Med. 2020 Oct;34(10):718-724
pubmed: 32656648
J Urol. 2000 Jun;163(6):1693-6
pubmed: 10799162
Eur Urol. 2014 Mar;65(3):600-9
pubmed: 24355132
J Urol. 2020 Aug;204(2):254-259
pubmed: 32134343
BJU Int. 2014 May;113(5b):E39-48
pubmed: 24053715
Curr Urol Rep. 2016 Oct;17(10):74
pubmed: 27539291
BMC Urol. 2015 Aug 21;15:87
pubmed: 26294219
Clin Genitourin Cancer. 2017 Jun;15(3):e405-e409
pubmed: 28007368
Int J Clin Oncol. 2011 Jun;16(3):179-85
pubmed: 21526392
Eur Urol. 2011 Nov;60(5):946-52
pubmed: 21802833
Minerva Urol Nefrol. 2016 Apr;68(2):138-49
pubmed: 27271230
Urol Oncol. 2017 Oct;35(10):606.e9-606.e16
pubmed: 28676151
Curr Urol Rep. 2013 Apr;14(2):124-9
pubmed: 23341374
Eur Urol. 2007 Jun;51(6):1511-20; discussion 1520-1
pubmed: 17275167
Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):386-93
pubmed: 23179944
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):329-37
pubmed: 16220303
Eur Urol. 2006 Jan;49(1):59-70
pubmed: 16321468
Semin Nucl Med. 2004 Oct;34(4):274-92
pubmed: 15493005
Indian J Urol. 2015 Jul-Sep;31(3):170-5
pubmed: 26166959
J Magn Reson Imaging. 2017 Nov;46(5):1281-1288
pubmed: 28199039
Nanomedicine (Lond). 2015;10(7):1189-201
pubmed: 25929573
J Urol. 2001 Sep;166(3):812-5
pubmed: 11490224
Cancer. 2008 Dec 15;113(12 Suppl):3519-29
pubmed: 19058151
Urology. 2012 Dec;80(6):1313-8
pubmed: 23040723
Eur Urol. 2013 Dec;64(6):953-60
pubmed: 23916692
Qual Life Res. 2005 May;14(4):1007-23
pubmed: 16041897
J Urol. 1986 Oct;136(4):825-7
pubmed: 3761439
Eur Urol. 2014 Dec;66(6):1065-77
pubmed: 25074764
Scand J Urol Nephrol. 1986;20(4):261-5
pubmed: 3810056
Urology. 2014 Apr;83(4):824-9
pubmed: 24680450
BJU Int. 2014 Sep;114(3):389-95
pubmed: 24341486
Urol Oncol. 2014 Nov;32(8):1184-90
pubmed: 25027683
Eur Urol. 2012 Feb;61(2):237-42
pubmed: 22033174
Cancer. 1977 Feb;39(2):456-66
pubmed: 837331
BJU Int. 2010 Sep;106(5):658-63
pubmed: 20151968
J Surg Oncol. 2014 Dec;110(7):845-50
pubmed: 25111761
Eur Urol. 2009 Apr;55(4):761-9
pubmed: 19144456
Clin Nucl Med. 2016 Aug;41(8):e362-7
pubmed: 27055134
Minerva Urol Nefrol. 2018 Aug;70(4):361-369
pubmed: 29241310
Eur Urol. 2019 Apr;75(4):604-611
pubmed: 30337060
BJU Int. 2012 Apr;109(7):1031-6
pubmed: 21883835
BJU Int. 2017 Sep;120(3):329-336
pubmed: 27797436
World J Urol. 2019 Apr;37(4):667-690
pubmed: 30120501
Eur Urol. 2012 May;61(5):1025-30
pubmed: 22342773
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
Radiology. 2004 Nov;233(2):449-56
pubmed: 15375228
J Clin Oncol. 2011 Jun 1;29(16):2171-7
pubmed: 21502557
Int J Gynecol Cancer. 2006 Mar-Apr;16(2):649-54
pubmed: 16681741
Eur J Surg Oncol. 2015 Jan;41(1):1-20
pubmed: 25454828
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Eur J Cancer. 2013 Feb;49(3):616-24
pubmed: 23084842

Auteurs

Ankit Sinha (A)

Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage SG1 4AB, UK.

Alexander West (A)

Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage SG1 4AB, UK.

John Hayes (J)

Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage SG1 4AB, UK.

Jeremy Teoh (J)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.

Karel Decaestecker (K)

Department of Urology, University of Ghent Hospital, 9000 Ghent, Belgium.

Nikhil Vasdev (N)

Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage SG1 4AB, UK.
School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH